# Clonal spread of *Plasmodium falciparum* candidate artemisinin partial resistance *Kelch13* 622I mutation and co-occurrence with *pfhrp2/3* deletions in Ethiopia

- 3 Abebe A. Fola<sup>1,2\*</sup>, Sindew M. Feleke<sup>3\*</sup>, Hussein Mohammed<sup>3</sup>, Bokretsion G. Brhane<sup>3</sup>, Christopher M.
- 4 Hennelly<sup>4</sup>, Ashenafi Assefa<sup>3,4</sup>, Rebecca M. Crudal<sup>1,2</sup>, Emily Reichert<sup>5</sup>, Jonathan J. Juliano<sup>4</sup>, Jane
- 5 Cunningham<sup>6</sup>, Hassen Mamo<sup>7</sup>, Hiwot Solomon<sup>8</sup>, Geremew Tasew<sup>3</sup>, Beyene Petros<sup>7</sup>, Jonathan B Parr
- 6 <sup>4</sup>\* Jeffrey A. Bailey <sup>1,2</sup>\*
- 7 (\* co-first and senior authors)
- 8

# 9 Affiliations

- 10 <sup>1</sup>Center for Computational Molecular Biology, Brown University, Providence, RI, USA
- <sup>2</sup>Department of Pathology and Laboratory Medicine, Warren Alpert Medical School, Brown University,
- 12 Providence, RI, USA
- 13 <sup>3</sup>Ethiopian Public Health Institute, Addis Ababa, Ethiopia
- <sup>4</sup>Institute for Global Health and Infectious Diseases, University of North Carolina, Chapel Hill, NC, USA
- <sup>5</sup>Harvard T. H. Chan School of Public Health, Harvard University, Boston, MA, USA
- <sup>6</sup>Global Malaria Programme, World Health Organization, Geneva, Switzerland
- <sup>7</sup>Department of Microbial, Cellular and Molecular Biology, College of Natural and Computational Sciences,
- 18 Addis Ababa University, Addis Ababa, Ethiopia
- 19 <sup>8</sup>Federal Ministry of Health, Addis Ababa, Ethiopia
- 20

# 21 Corresponding:

- 22 Jeffrey A. Bailey, MD, PhD
- 23 Mencoff Family Associate Professor of Translational Research, Associate Professor of Pathology and
- 24 Laboratory Medicine
- 25 Box G-E5, Providence, RI 02912, USA
- 26 Tel: 401-444-5160
- 27 Fax: 401-444-4377
- 28 Email: jeffrey\_bailey@brown.edu
- 29

30 Key words: Kelch13, 622I, Pfhrp2/3-deletion, Ethiopia, Malaria

# 32 Abstract

The emergence and spread of drug- and diagnostic-resistant Plasmodium falciparum are major impediments to malaria control and elimination. We deep sequenced known drug resistance mutations and other informative loci across the genome of 609 samples collected during a study across three regions of Ethiopia. We found that 8.0% (95% CI 7.0-9.0) of malaria cases were caused by P. falciparum carrying the candidate artemisinin partial-resistance K13 622I mutation, which occurred less commonly in diagnostic-resistant pfhrp2/3-deleted than normal non-deleted parasites (p=0.03). Identity-by-descent analysis showed that 622I parasites were significantly more related than wild-type (p<0.001), consistent with recent expansion and spread. Pfhrp2/3-deleted parasites were also highly related, with evidence of clonal transmissions at the district level. Parasites carrying both pfhrp2/3 deletion and 622I mutation were observed in some sites. These findings raise concern for future spread of combined drug- and diagnostic-resistant parasites and warrant close monitoring. 

- -

### 58 Introduction

59 Despite intensified malaria control efforts, progress toward elimination has stalled in recent years. Malaria cases increased across many endemic countries in Africa, where 96% of malaria deaths occur primarily 60 61 due to Plasmodium falciparum<sup>1</sup>. The World Health Organization (WHO) recommends artemisinincombination therapies (ACTs), such as artemether-lumefantrine (AL) or artesunate-amodiaquine (AS-62 AQ), as the first-line treatments for uncomplicated P. falciparum malaria<sup>2</sup>. However, the parasite has 63 evolved drug resistance to most available antimalarial drugs<sup>3,4</sup> and history demonstrates that resistant 64 strains can rapidly spread<sup>5,6</sup>. Since 2008, P. falciparum parasites resistant to first-line ACTs have emerged 65 in Southeast Asia<sup>7,8</sup> and have spread to neighboring regions<sup>9,10</sup>. 66

67 Increasing reports across Africa indicate reduced efficacy of artemisinins, with slowed clearance times and increased recrudescences<sup>11-14</sup>. Mutations in kelch13 (K13) associated with partial resistance to artemisinins 68 have now also been reported in Uganda, Tanzania and Rwanda<sup>15–17</sup>. In addition, parasites undetectable by 69 widely used P. falciparum rapid diagnostic tests (RDTs), owing to deletion mutations of the histidine-rich 70 proteins 2 and 3 (*pfhrp2/3*) genes, have emerged in the Horn of Africa<sup>18–20</sup>. Together, these mutations 71 threaten both components of existing test-and-treat programs, as co-occurrence of pfhrp2/3 deletions and 72 73 K13 mutations would yield parasites resistant to both diagnosis and treatment. Improved understanding of 74 how these mutations emerge, interact, and spread is critical to the success of future malaria control and 75 elimination efforts across Africa.

In Ethiopia, malaria is endemic across 75% of the country, with 65% of the population at risk<sup>21</sup>. Over five 76 million episodes of malaria occur each year, but transmission is highly heterogeneous and seasonal<sup>22</sup>. 77 Prompt diagnosis and treatment with efficacious drugs is a cornerstone of the malaria program<sup>23</sup>. ACTs 78 79 are first-line treatment for uncomplicated falciparum malaria since 2004 throughout the country. However, 80 chloroquine (CQ) is still widely used and efficacious for cases of endemic vivax malaria<sup>24</sup>. Artemetherlumefantrine remains highly efficacious<sup>25</sup>, though detection of the candidate artemisinin resistance K1381 622I mutation in northern Ethiopia<sup>26,27</sup> and high prevalence of residual submicroscopic parasitemia 82 83 following ACT treatment in recent studies raises concern<sup>12,25</sup>.

Countries such as Ethiopia provide important opportunities to investigate the impact of drug and diagnostic resistance mutations and how they may co-evolve and spread. To our knowledge, there are no published studies addressing the prevalence of drug resistance mutations among *pfhrp2/3*-deleted versus non-deleted

strains, nor their transmission patterns. We sought to bridge this knowledge gap by conducting a comparative genomic analysis of drug resistance among *pfhrp2/3*-deleted and non-deleted parasites collected across three regions of Ethiopia. Using molecular inversion probe (MIP) sequencing for highlymultiplexed targeted genotyping<sup>28,29</sup>, we determine the prevalence of key drug resistance mutations and detect spatial patterns of related 622I mutant and *pfhrp2/3*-deleted *P. falciparum* strains. We demonstrate a high prevalence of the 622I mutation across three regions and co-occurrence with *pfhrp2/3* deletion in Ethiopia as well as clonal transmission of *pfhrp2/3* deleted parasites at district level.

94

### 95 **Results**

# 96 MIP sequence data filtering and complexity of infections estimation

97 A total of 920 samples previously genotyped and MIP sequenced for *pfhrp2/3* deletions from three regions of Ethiopia (Amhara = 598, Gambella = 83, Tigray = 239) (Supplementary Figure S1) were included in 98 99 this analysis, representing dried blood spots taken from a subset of the overall series of 2637 malaria cases 100 (Amhara = 1336, Gambella = 622, Tigray = 679) (Table S1). Samples had been collected from rural areas in 12 districts as part of a large pfhrp2/3 deletion survey of those 12,572 study participants (56% male, 101 44% female, age ranges 0 and 99 years) presenting with clinical signs and symptoms of malaria<sup>18</sup>. For this 102 103 study, all samples were further MIP captured and sequenced using both i) a drug resistance panel 104 comprising 814 probes designed to target mutations and genes associated with antimalarial resistance and 105 ii) a genome-wide SNP panel comprising 1832 probes designed for assessment of parasite relatedness and 106 connectivity (Supplementary Data 1 and 2). Parasite densities across samples ranged from 3 to 138.447 107 parasites/µl with median parasitaemia of 1,411 parasites/µl (Supplementary Figure S2A); as expected, 108 MIP sequencing coverage was parasite density-dependent (Supplementary Figure S2B). All resistance 109 genotypes with sufficient depth and quality were included in downstream analysis. After filtering for 110 sample missingness and removing loci with low coverage (Supplementary Figure S3), 609 samples and 111 1395 SNPs from the genome-wide panel (Supplementary Figure S4, Supplementary Data 3 and 4) 112 were included in downstream relatedness analysis.

Using filtered genome-wide SNPs, we calculated complexity of infection (COI) and adjusted for the relative proportion of DBS sampled from participants with discordant vs. concordant RDT results since the parent *pfhrp2/3* survey purposefully oversampled the former. We estimate that the majority (82.4%)

of cases are monogenomic infections (COI = 1) (**Supplementary Figure S5, Table S1**), reflecting relatively low ongoing transmission in the study areas. Overall, COI per sample ranged from 1 to 4 with variability at the district level (**Supplementary Figure S5C**), consistent with heterogeneous malaria transmission at local scale.

## 120 K13 622I mutation is prevalent in Ethiopia across all regions sampled

121 Analysis of the drug-resistance markers revealed a high prevalence (8.0%, [95% confidence interval (CI) 122 7.0-9.0]) of samples expected to carry the WHO candidate artemisinin partial resistance mutation 622I 123 within the propeller domain of K13. The 622I mutation had only been previously described in Africa at a single site in Amhara near the Sudan border in 2014 at 2.4% prevalence<sup>26</sup>. Our results confirmed parasites 124 125 with 622I in all 3 regions surveyed as well as all 12 districts (Figure 1A). Highest prevalence was observed 126 in Amhara (9.8%, [95% CI 8.2-11.4]) in the northwest near the Sudan border, followed by Tigray (8.4%, 127 [95% CI 6.2-10.5]) near the Eritrea border, and Gambella (3.6%, [95% CI 2.1-4.8]) bordering South Sudan, 128 however, there was high spatial heterogeneity at the district level and within regions (Table S1). An 129 additional 8 non-synonymous mutations were identified across the K13 gene at low frequencies (<3%) 130 except for K189T (44.4%), which is frequently observed in Africa and not associated with resistance 131 (Figure 1B). None of the other mutations were WHO-validated or candidate artemisinin partial resistance 132 mutations, and only two (K13 E401Q and E433D) fell within the propeller region (Figure 1B, bottom 133 panel, Supplementary Table S1). To gain insight into relative fitness of 622I, we compared within-134 sample allele proportions in mixed mutant and wild-type infections (n = 16). On average, wild-type parasites occured at relatively higher proportions (mean = 0.59) compared with 622I mutant parasites 135 136 (mean = 0.41) (Mann-Whitney p = 0.025) in participants infected by more than one strain, suggesting lower fitness of mutant strains. The power of this analysis was limited as polygenomic infections were rare 137 138 in this study but is consistent with competitive blood stage fitness costs.

# 139 *K13* 622I mutant parasites carry background mutations that may augment ACT resistance

In addition to *K13* mutations, we found a number of key mutations in other *P. falciparum* genes associated
with resistance to different antimalarial drugs (Figure 1C, Table S2), including ACT partner drugs.
Mutations in the *P. falciparum* multidrug resistance gene 1 (*pfmdr1*), particularly isolates that carry the
NFD haplotype (N86Y (wild), Y184F (mutant), and D1246Y (wild)) have been associated with decreased
sensitivity to lumefantrine<sup>30</sup>. Overall, 83% of samples carry the NFD haplotype (Figure 2), and 98%

145 (60/61) of 622I mutant parasites carry pfmdr1 NFD haplotypes. Although this difference was not 146 significant (Fisher's exact p = 0.34), the presence of 622I mutant parasites with *pfmdr1* NFD haplotypes 147 raises questions about how the genetic background of 622I influences ACT efficacy in Ethiopia. We also investigated other mutations previously identified as backbone loci on which artemisinin partial resistance 148 149 associated K13 mutations are most likely to arise or could augment ACT resistance<sup>31</sup>. No parasites sampled 150 in this study carried such background mutations (pffd-D193Y, pfcrt-I356T, pfarps-V127M and pfmdr2-151 T484I), with the exception of pfcrt-N326S, which 98% of K13 622I and 81% of wild-type parasites carried 152 (Fisher's exact p < 0.001) (Figure 2). The co-occurrences of 622I with the *pfmdr1* NFD haplotype and pfcrt-N326S raise concern about the efficacy of both artemisinin and partner drugs like lumefantrine in 153 154 Ethiopia. We also observed drug-resistance mutations in other genes (Table S3), with high prevalence and 155 some spatial heterogeneity in the distribution of mutations associated with sulfadoxine-pyrimethamine 156 (SP) resistance (Supplementary Figure S6).

#### 157 **Co-occurrence** of drug-resistance mutations and *pfhrp2/3* deletions

158 Overall, the K13 622I mutation is more common among pfhrp2/3 non-deleted parasites (26/223, 11.6%) 159 than *pfhrp2/3* double-deleted parasites (5/110, 4.5%), though not significantly (Fisher's exact p = 0.07). 160 However, higher mean prevalence of 622I mutation is observed among pfhrp2/3 non-deleted parasites at 161 the district level (T-test p = 0.03) (Figure 3A), which could be consistent with deleterious effects from the 162 combination and/or independent origins with slow intermixing. We repeated this analysis using 163 permutation by randomly reassigning double- and non-deleted groups and took the mean difference of these new groups. The permutation analysis shows -8.7% mean difference (F-statistic p = 0.02) in 164 165 prevalence of 622I among pfhrp2/3-deleted vs. non-deleted parasites, suggesting patients infected by 166 double-deleted parasites are more likely misdiagnosed and less likely receive ACTs according to the 167 country test and treat policy that result in less ACT drug pressure. We observed a negative correlation 168 between these mutations at the level of the individual collection sites, suggesting different sites generally harbor one mutation or the other at high frequency. However, we observed a small number (n = 5) of 169 170 parasites with both 622I mutation and pfhrp2/3 deletion in sites where mutation or deletion frequency is 171 high (Figure 3B), confirming that recombination between parasites with these mutations is possible. Interestingly, 622I is more common among pfhrp3-deleted parasites (29/169, 17.2%) compared to 172 173 wildtype pfhrp2/3 non-deleted (26/223, 11.2%) but the difference was not statistically significant (Chi-174 square p = 0.23).

175 We also examined co-occurrence of pfhrp2/3 deletions and other drug resistance mutations, particularly 176 *pfcrt* mutations as most *pfhrp2/3* deletion reports to-date have emerged in areas where P. vivax and P. falciparum are sympatric and chloroquine is used to treat vivax malaria<sup>32</sup>. We observed overall high 177 prevalence (median 84% across districts) of *pfcrt* mutations (codon 74-76) (Supplementary Figure S7A). 178 179 The prevalence of pfcrt-K76T mutation was greater among pfhrp2/3-deleted (96.3%) compared to nondeleted (73.8%) parasites, but the difference was not statistically significant (Chi-square p = 0.15, 180 181 Supplementary Figure S7B). This finding suggests patients infected by *pfhrp2/3*-deleted parasites may 182 be more often exposed to chloroquine.

#### 183 Population structure of *K13* 622I and *pfhrp2/3*-deleted *P. falciparum* in Ethiopia

184 We investigated genetic population structure using principal component analysis (PCA), which revealed 185 clustering of parasites by K13 622I mutation (PC1) and by pfhrp2/3 deletion (PC2) status, but not by 186 geography (Figure 4, Supplementary Figure S8A). Overall, 13.4% of variation in our dataset was 187 explained by these first two principal components (Supplementary Figure S8B). Analysis of loading 188 values did not reveal SNPs or genomic regions with disproportionate influence on the observed population 189 structure (Supplementary Figure S9). Genetic differentiation between populations is low overall ( $F_{st}$ 190 range = 0.002 - 0.008), and lowest between Amhara and Tigray regions ( $F_{st} = 0.002$ ) and highest between 191 Gambella and Tigray regions ( $F_{st} = 0.008$ ), followed by between Amhara and Gambella ( $F_{st} = 0.003$ ).

### 192 Genetic relatedness of *K13* 622I mutant and *pfhrp2/3*-deleted parasites

193 IBD analysis revealed evidence of recent clonal transmission and spread of K13 622I parasites. Overall, 194 10.6% of pairs are highly-related (IBD  $\geq$  0.25, half siblings) (Figure 5A). We observe a tailed distribution 195 of highly related parasite pairs, with 26.6% of pairwise comparisons sharing their genome with an IBD 196 value of > 0.05. Comparing K13 622I mutant and wild-type parasites, we find significantly higher mean 197 pairwise IBD sharing within K13 622I mutant populations (0.43 vs 0.08, respectively, Mann-Whitney  $p < 10^{-10}$ 198 0.001) (Figure 5B). Network analysis of highly related parasites (pairwise IBD  $\geq$  0.95) shows that 622I 199 mutant parasites tend to form related clusters and pairs separate from wild-type parasites (Figure 5C), 200 consistent with clonal transmissions of 622I parasite populations in Ethiopia. The majority of clonal 201 parasites carrying 622I mutation originated from one district (Tegede) (Figure 5D), likely illustrating an 202 outbreak with rapid spread (Table S1).

203 *Pfhrp2/3*-deleted parasites also have higher relatedness than wild-type parasites, with significantly 204 different pairwise IBD sharing (Kruskal-Wallis test p < 0.001) when comparing *pfhrp2/3* double-, single-205 , and non-deleted parasites (Figure 6A). Pairwise IBD sharing is highest among *pfhrp2/3* double-deleted parasites, with 43.7% of comparisons having IBD  $\geq 0.25$  (half siblings), compared to only 4.3% of 206 207 *pfhrp2/3* non-deleted parasites. Network analysis of highly related isolates (IBD  $\geq 0.95$ ) revealed 208 clustering by deletion status (Figure 6B) with district-level clustering of *pfhrp2/3*-double deleted parasites 209 evident in Kule, Atse-Tshimbila and West-Armachiho (Figure 6C), a finding consistent with clonal spread 210 of *pfhrp2/3*-double deleted parasites at the local scale.

#### 211 Discussion

212 Our genetic analysis confirms a widely prevalent WHO candidate artemisinin partial resistance K13 622I 213 mutation across three regions of Ethiopia and suggests recent clonal spread. We observe low levels of polyclonality in this study consistent with previous study findings<sup>24</sup> and relatively low to moderate level 214 215 malaria transmission intensity in these regions. Our findings suggest that independent transmission of 216 highly related 622I or diagnostic-resistant pfhrp2/3-deleted parasites predominates with bursts of clonal 217 spread. These findings suggest that Ethiopia's intensive test-and-treat strategies have exerted significant 218 selective pressure on the P. falciparum population and are driving rapid expansion of artemisinin and 219 diagnostic-resistant parasites. Though rare, identification of parasites carrying both 622I and pfhrp2/3 220 deletion mutations raises concern that parasites with partial resistance to treatment and the ability to escape 221 HRP2-based RDT detection are circulating in Ethiopia.

222 The presence of K13 622I across all sampled districts signals that parasites are under ACT pressure in 223 Ethiopia and indicates that parasites are evolving to escape antimalarial treatment. The 622I mutation was 224 reported previously in two small studies from one site in northern Ethiopia (Gondar), with associated delay in parasite clearance on day 3 of ACT<sup>26</sup> and increased prevalence over time, from 2.4% in 2014<sup>26</sup> to 9.5% 225 in 2017-18<sup>27</sup>. While not yet peer reviewed, reports of 622I at high prevalence in Eritrea (16.7% in 2016) 226 227 and association with 6.3% delayed clearance on day 3 of AL treatment raise further concern about this 228 mutation<sup>33</sup>. The higher prevalence of the 622I mutation in northern Ethiopia (Amhara region) in our study 229 suggests that it originated in northern Ethiopia or Eritrea, though our data are insufficient to determine its 230 origins. The lower frequency of 622I vs. wild-type parasites in polyclonal infections provides evidence 231 that it may decrease fitness within the human host, a consistent trait of artemisinin partial resistance

mutations due to loss of function within the K13 propeller. Taken together, these findings suggest that 622I in Ethiopia represents a meaningful threat to elimination efforts across the Horn of Africa.

234 As transmission declines in Ethiopia and other settings nearing elimination, the majority of infected 235 individuals are expected to carry single rather than multiple parasite strains. 82% of genotyped samples in our study are monogenomic, consistent with previous findings<sup>24</sup>. The associated increased rate of 236 inbreeding in such settings<sup>34</sup> is known to favor the spread of drug-resistant strains<sup>35,36</sup>. Decreased parasite 237 competition in low-transmission settings allows strains with resistance mutations that make them relatively 238 239 less fit in the absence of drug pressure to expand. This is the case for artemisinin partial resistance. We 240 previously showed that false-negative HRP2-based RDT results owing to *pfhrp2/3* deletions are common in Ethiopia and that *pfhrp2* deletion is under recent positive selection<sup>18</sup>. Using a larger MIP panel targeting 241 242 SNPs across the genome for IBD analysis, we now found that these parasites are closely related and that 243 bursts of clonal transmission appear to be occurring at the district or local scale. These findings support 244 the idea that low transmission and associated parasite inbreeding are important for the expansion of 245 pfhrp2/3-deleted populations. This also is consistent with the idea that outcrossing may disrupt co-246 transmission of *pfhrp2* and *pfhrp3* deletions given they are on separate chromosomes. The rare presence 247 of parasites with both K13 622I and pfhrp2/3 deletion mutations is not a reassuring finding. Their co-248 existence in a small number of parasites may simply be a consequence of their distinct origins and 249 insufficient time for the expansion of 622I, pfhrp2/3-deleted parasite strains. While combined fitness costs may also play a role in the low prevalence of parasites with both mutations<sup>16,37</sup>, in the absence of inter-250 251 strain competition in low transmission settings, there are likely few barriers to the spread of 622I, pfhrp2/3-252 deleted parasites. Our expanded genetic analysis of drug-resistance mutations and parasite population 253 structure confirms that close monitoring of emerging drug- and diagnostic-resistant strains is urgently 254 needed to inform control strategies in the Horn of Africa and neighboring countries.

Different studies suggested that high efficacy of partner drugs (i.e. lumefantrine) impede the spread of ACT resistance in Africa<sup>16,37</sup>. However, we observe high prevalence of mutations associated with resistance to other antimalarial drugs our study, with nearly all genotyped samples carrying the ACT partner drug lumefantrine resistance haplotype  $(pfmdrl NFD)^{38,39}$  and more than 80% carrying the *pfcrt* N326S background mutation that augments artemisinin partial resistance. No parasites sampled in this study carried other common background mutations observed in SEA (*pffd*-D193Y, *pfcrt*-I356T, *pfarps*-

V127M and *pfmdr2*-T484I)<sup>31</sup>. Together, these findings support the need for close monitoring of
 lumefantrine efficacy and other partner drugs across Ethiopia.

263 IBD sharing was higher within the K13 622I mutant parasite population compared to wild-type parasites, suggesting that 622I mutation emerged or entered into northern Ethiopia in the recent past<sup>27</sup> and spread to 264 265 other parts of the country. Highly related parasites are also closely clustered at the district level, a finding 266 expected after clonal transmission. Moreover, our finding of parasites with high IBD and low overall COI 267 in this study indicates low ongoing transmission across the three regions and that most recombination is between highly-related or clonal strains<sup>40,41</sup>. IBD analysis also showed high relatedness and clonal 268 269 expansion of pfhrp2/3 double-deleted parasites (most likely not detected by HRP2-based RDTs) at the 270 local scale, with distinct populations of very closely related *pfhrp2/3*-deleted parasites observed in several 271 districts. Clonal spread with local inbreeding could facilitate rapid spread of *pfhrp2/3*-deleted parasites 272 that are expected to escape diagnosis by RDTs. Our data also reveals higher prevalence of 622I mutation 273 among pfhrp 2/3 non-deleted compared to double-deleted parasites, a finding that might be seen when 274 pfhrp2/3 deletion leads to misdiagnosis, leaves patients untreated, and results in pfhrp2/3-deleted parasites 275 exposed to less ACT pressure. Supporting this idea, we observed more frequent co-occurrence of pfcrt-276 K76T mutation suggestive of empirical chloroquine treatment for presumed non-falciparum malaria.

277 Our study is not without limitations. First, travel histories from malaria cases and samples from 278 neighboring countries are not included and thus tracking resistant strain importation is not addressed in 279 detail. Second, the parent study was designed to evaluate RDT failure and could introduce selection bias, 280 including under sampling of low-parasitemia and submicroscopic infections or oversampling of 281 monogenomic infections. We therefore adjusted our K13 622I prevalence estimates to improve the 282 generalizability of our findings. Third, the areas studied represent regions with relatively higher transmission (Amhara, Gambella and Tigray) and do not include other parts of the country, making it 283 284 difficult to extrapolate our findings across the country. It may be that other regions have lower prevalences 285 of drug and diagnostic resistance mutations, or that prevalences are even higher in lower transmission 286 settings. Further study within Ethiopia and surrounding countries is warranted.

Overall, our study provides evidence that the ongoing selective pressures exerted on parasite populations in Ethiopia by HRP2-based RDT diagnosis<sup>42</sup> and ACT treatment<sup>43</sup> could facilitate co-occurrence of diagnostic and drug resistance, representing a double threat to malaria elimination. Ethiopia's recent

transition to alternative RDTs may reduce selective pressures favoring *pfhrp2/3*-deleted strains. However, we observe 622I mutation in multiple regions alongside *pfhrp2/3*-deleted parasites, and concerning examples of co-occurrence that could yield parasites resistant to both diagnosis and treatment. As Ethiopia and other countries in the Horn of Africa approach malaria elimination, diagnostic and drug resistance may be more likely to co-occur. These findings also illustrate the value of targeted parasite genomic analysis as part of large-scale malaria surveys and demonstrate the need for close monitoring of ACT efficacy that includes advanced molecular surveillance in Ethiopia.

#### 297 Materials and Methods

# 298 Study sites and sample genotyping

A total of 920 samples from three regions (Amhara = 598, Gambella = 83 and Tigray = 239) 299 (Supplementary Figure S1) previously assessed for pfhrp2/3 deletions<sup>18</sup> were further genotyped using 300 301 molecular inversion probes (MIPs). Sampling strategy, samples collection, DBS samples transportation, DNA extraction and initial molecular analysis were described in detail in our previous study<sup>18</sup>. The parent 302 303 study was approved by the Ethiopian Public Health Institute (Addis Ababa, Ethiopia; protocol EPHI-IRB-304 033-2017) and the World Health Organization Research Ethics Review Committee (Geneva, Switzerland; 305 protocol ERC.0003174 001). Parasite sequencing and analysis of de-identified samples was deemed 306 nonhuman subjects research by the University of North Carolina at Chapel Hill (NC, USA; study 17-0155).

# 307 MIP capture, sequencing and variant calling

308 DNA originally isolated from DBS samples were captured and sequenced using two separate MIP panels: 309 (1) a drug resistance panel (n = 814) designed to target mutations and genes associated with antimalarial 310 resistance, and (2) a genome-wide panel (n = 1832) designed to target SNPs to evaluate parasite 311 connectivity and relatedness (**Supplementary Data 1** and **2**)<sup>28,44</sup>. MIP capture and library preparation were 312 performed as previously described<sup>17</sup>. Sequencing was conducted using an Illumina NextSeq 550 313 instrument (150 bp paired-end reads) at Brown University (RI, USA).

The MIPtools (v0.19.12.13; <u>https://github.com/bailey-lab/MIPTools</u>) bioinformatic pipeline was used for processing of sequencing data and variant calling. Briefly, this pipeline employs MIPWrangler software to stitch paired reads, remove sequence errors, and predict MIP microhaplotypes leveraging the unique molecular identifiers (UMIs) in each arm. The haplotypes for each target were mapped to the *P. falciparum* 

3D7 reference genome (PlasmoDB-42 Pfalciparum3D7) using Burrows-Wheeler Aligner (BWA)<sup>45</sup> and 318 variant calling was performed on these samples using freebayes<sup>46</sup>. Downstream analyses were performed 319 320 on generated variant calling files (VCF) as well as translated tables based on 3D7 transcriptome for coding 321 mutations. For genome-wide MIP panel, variants were quality filtered by removing those with less than 322 three UMIs within a sample and less than 10 UMIs across the entire population. The drug resistance panel 323 included known SNPs in pfcrt, pfdhfr, pfdhps, pfmdr1, K13 and other putative drug resistance genes and 324 has been described elsewhere<sup>28</sup> (Supplementary Data 2). First prevalence was calculated as (p = m/n\*100, p)325 where p = prevalence, m = number of infections with mutant alleles, <math>n = number of successfully genotyped326 infections) (Table S3). Unweighted prevalence was calculated using the miplicorn R package version 327 0.2.90 (https://github.com/bailey-lab/miplicorn) and vcfR R package version 1.13.0<sup>47</sup>. Mutant combinations were plotted and visualized using UpSet Package in R version 1.4.048. Because dried blood 328 329 spot sampling differed based on RDT results (participants with HRP2-/PfLDH+ results were purposefully 330 oversampled for molecular characterization in the parent study), we adjusted our K13 622I prevalence 331 estimates by weighting for the relative sampling proportions of RDT-concordant (HRP2+) and discordant (HRP2-/PfLDH+) samples. This was achieved by weighting RDT profile-specific prevalence estimates by 332 333 the total number of *P. falciparum*-positive individuals presenting with that RDT profile in the parent study 334 by district, region, and overall. Finally, 95% confidence intervals for these weighted prevalence estimates 335 were estimated using bias corrected and accelerated (BCa) bootstrapping (n = 2000 replications for district 336 and region-level estimates, n = 3000 replications for overall study estimate) using the R packages boot 337 (version 1.3-28) and confintr (version 0.2.0). Mutant combinations were plotted and visualized using UpSet Package in R version 1.4.0<sup>48</sup>. For the genome-wide MIP panel, only biallelic variant SNPs were 338 339 retained for analysis. Genome positions with more than 50% missing data (Supplementary Figure S3A), 340 and samples missing 50% of sites (Supplementary Figure S3B) were removed leaving 609 samples and 341 1395 SNPs from the genome-wide panel (Supplementary Figure S4A), which are distributed across 14 342 P. falciparum chromosomes (Supplementary Figure S4B). The drug resistance panel includes SNPs across known P. falciparum drug resistance genes that have been described elsewhere<sup>28</sup>. 343

# 344 Complexity of infection analysis (COI)

To estimate the COI, we used THE REAL McCOIL R package categorical method<sup>49</sup>. As DBS sampling in the parent study favored RDT discordant samples (HRP2-/pfLDH+) and could bias our COI estimates, we estimated overall and district level prevalence of monogenomic infections by weighting for the relative

348 sample proportions of RDT concordant and discordant samples in the parent survey. We also calculated within-host fixation index (F<sub>ws</sub>) using R package moimix 2.9<sup>50</sup> as another measure of within-host diversity 349 350 of the parasites, which measures the probability that any random pair of infections carry different alleles at a specific locus. It was calculated for each infection as follows,  $F_{ws} = 1$ -(Hw/Hs), where Hw is the 351 352 infection heterozygosity across all loci and Hs is the heterozygosity of the population from which the 353 infection was sampled. As Fws calculation based on the frequency of alleles per individual compared to 354 that within the source population, it allows comparison between populations. Fws range from 0 to 1, the sample was classified as having multiple infections (polyclonal) if  $F_{ws} < 0.95$  and monoclonal (single 355 356 strain) infections if  $F_{ws} \ge 0.95$ . Samples with  $F_{ws} < 0.95$  were considered to come from mixed strain 357 infections, indicating within-host diversity.

#### 358 **Population structure and genetic differentiation**

To assess whether parasite populations within Ethiopia clustered based on their geographic origin, or pfhrp2/3 deletion status, we first conducted principal component analysis (PCA) using SNPRelate R package version 1.30.1<sup>51</sup>. The eigenvalues generated from filtered VCF using snpgdsPCA function used as input file and the result was visualized using ggplot2 R package version 3.4.0. We calculated pairwise genetic differentiation (*F*<sub>ST</sub>) as a measure of genetic divergence between populations using PopGenome R package version 2.7.5<sup>52</sup>.

#### 365 Analysis of parasite relatedness using Identity-by-Descent (IBD)

To measure relatedness between *P. falciparum* parasites and identify regions of the genome shared with recent common ancestry, the inbreeding\_mle function of the MIPAnalyzer software version 1.0.0 was used on monogenomic samples to calculate IBD<sup>44</sup>. We determined IBD sharing variation at regional and local scale (district level) to assess spatial patterns of parasite connectivity and transmission dynamics at microlocal level comparing deleted and mutant parasites vs wild-type. Networks of highly-related parasites per *K13* 622I mutation status or *pfhrp2/3* deletion status were generated using the igraph R package version 1.3.5<sup>53</sup>.

# 373 Conflicts of Interest

- 374 JBP reports research support from Gilead Sciences, non-financial support from Abbott Diagnostics, and
- 375 consulting from Zymeron Corporation, all outside the scope of the current work. Other authors do not have
- a relevant conflict of interest to report.

# 377 Funding

This project was funded in part by the US NIH (R01AI132547 and K24AI134990 to J.J.J). The parent study was funded by the Global Fund to Fight AIDS, Tuberculosis, and Malaria through the Ministry of Health-Ethiopia (EPHI5405 to S.M.F.) and by the Bill and Melinda Gates Foundation through the World Health Organization (OPP1209843 to J.C., J.B.P.), with partial support from MSF Holland which supported fieldwork in the Gambella region. Under the grant conditions of the Bill and Melinda Gates Foundation, a Creative Commons Attribution 4.0 Generic License has already been assigned to the Author Accepted Manuscript version that might arise from this submission.

#### 385 Acknowledgments

We thank the EPHI research teams for conducting the fieldwork during the parent study. We would alsolike to thank all of the participants and family members who contributed to this study.

# 388 Data Availability

All sequencing data available under Accession no. pending at the Sequence Read Archive (SRA)
(pending), and the associated BioProject alias is pending.

# **391** Author contributions

AAF, JBP, JJJ and JAB conceived the study. SF led the parent study, with contributions from MH, BG,
HM, BP, SH, JC, and JBP. AAF, CR, CH performed laboratory work. AAF led genetic data analysis and
wrote the first draft of the manuscript. JBP, JJJ and JAB supported genetic data analysis and interpretations
of results. All authors contributed to the writing of the manuscript and approved the final version before
submission.

## 398 References

- 399 1. World Health Organization. *World malaria report 2022*. (World Health Organization, 2022).
- 400 2. Ringwald, P., Shallcross, L., Miller, J. M., Seiber, E. & World Health Organization. Roll Back
- 401 Malaria Dept. Susceptibility of Plasmodium falciparum to antimalarial drugs : report on global
   402 monitoring 1996-2004. https://apps.who.int/iris/handle/10665/43302 (2005).
- Wellems, T. E. & Plowe, C. V. Chloroquine-resistant malaria. *The Journal of Infectious Diseases*vol. 184 770–776 Preprint at https://doi.org/10.1086/322858 (2001).
- 405 4. Ross, L. S. & Fidock, D. A. Elucidating mechanisms of drug-resistant *Plasmodium falciparum*. *Cell*406 *Host Microbe* 26, 35–47 (2019).
- 407 5. Takala-Harrison, S. & Laufer, M. K. Antimalarial drug resistance in Africa: key lessons for the
  408 future. *Ann. N. Y. Acad. Sci.* 1342, 62–67 (2015).
- 409 6. Anderson, T. J. C. & Roper, C. The origins and spread of antimalarial drug resistance: lessons for
  410 policy makers. *Acta Trop.* 94, 269–280 (2005).
- 411 7. Phyo, A. P. *et al.* Emergence of artemisinin-resistant malaria on the western border of Thailand: a
  412 longitudinal study. *Lancet* 379, 1960–1966 (2012).
- 413 8. Imwong, M. *et al.* The spread of artemisinin-resistant *Plasmodium falciparum* in the Greater
  414 Mekong subregion: a molecular epidemiology observational study. *Lancet Infect. Dis.* 17, 491–497
  415 (2017).
- 416 9. Roberts, L. Malaria wars. Science 352, 398–402 (2016).
- 10. Dhorda, M., Amaratunga, C. & Dondorp, A. M. Artemisinin and multidrug-resistant *Plasmodium falciparum* a threat for malaria control and elimination. *Curr. Opin. Infect. Dis.* 34, 432–439
  (2021).
- 420 11. Marwa, K. *et al.* Therapeutic efficacy of artemether-lumefantrine, artesunate-amodiaquine and
   421 dihydroartemisinin-piperaquine in the treatment of uncomplicated *Plasmodium falciparum* malaria
- 422 in Sub-Saharan Africa: A systematic review and meta-analysis. *PLoS One* **17**, e0264339 (2022).
- 423 12. Tadele, G. et al. Persistence of residual submicroscopic P. falciparum parasitemia following
- 424 treatment of artemether-lumefantrine in Ethio-Sudan Border, Western Ethiopia. *Antimicrob. Agents*425 *Chemother.* e0000222 (2022) doi:10.1128/aac.00002-22.
- 426 13. Ehrlich, H. Y., Bei, A. K., Weinberger, D. M., Warren, J. L. & Parikh, S. Mapping partner drug
  427 resistance to guide antimalarial combination therapy policies in sub-Saharan Africa. *Proc. Natl.*428 *Acad. Sci. U. S. A.* 118, (2021).

- 14. Ndwiga, L. *et al.* A review of the frequencies of *Plasmodium falciparum Kelch 13* artemisinin
  resistance mutations in Africa. *Int. J. Parasitol. Drugs Drug Resist.* 16, 155–161 (2021).
- 431 15. Uwimana, A. *et al.* Emergence and clonal expansion of in vitro artemisinin-resistant *Plasmodium*
- 432 *falciparum kelch13* R561H mutant parasites in Rwanda. *Nat. Med.* **26**, 1602–1608 (2020).
- 433 16. Balikagala, B. *et al.* Evidence of artemisinin-resistant malaria in Africa. *N. Engl. J. Med.* 385,
  434 1163–1171 (2021).
- 435 17. Moser, K. A. *et al.* Describing the current status of *Plasmodium falciparum* population structure and
  436 drug resistance within mainland Tanzania using molecular inversion probes. *Mol. Ecol.* **30**, 100–
  437 113 (2021).
- 438 18. Feleke, S. M. *et al. Plasmodium falciparum* is evolving to escape malaria rapid diagnostic tests in
  439 Ethiopia. *Nat Microbiol* 6, 1289–1299 (2021).
- 440 19. Berhane, A. *et al.* Major threat to malaria control programs by *Plasmodium falciparum* lacking
  441 histidine-rich protein 2, Eritrea. *Emerg. Infect. Dis.* 24, 462–470 (2018).
- Prosser, C. *et al. Plasmodium falciparum* histidine-rich protein 2 and 3 gene deletions in strains
  from Nigeria, Sudan, and South Sudan. *Emerg. Infect. Dis.* 27, 471–479 (2021).
- 444 21. Ayele, D. G., Zewotir, T. T. & Mwambi, H. G. Prevalence and risk factors of malaria in Ethiopia.
  445 *Malar. J.* 11, 195 (2012).
- 446 22. Taffese, H. S. *et al.* Malaria epidemiology and interventions in Ethiopia from 2001 to 2016. *Infect*447 *Dis Poverty* 7, 103 (2018).
- 448 23. Bugssa, G. & Tedla, K. Feasibility of malaria elimination in Ethiopia. *Ethiop. J. Health Sci.* 30,
  607–614 (2020).
- 450 24. Lo, E. *et al.* Transmission dynamics of co-endemic *Plasmodium vivax* and *P. falciparum* in Ethiopia
  451 and prevalence of antimalarial resistant genotypes. *PLoS Negl. Trop. Dis.* 11, e0005806 (2017).
- 452 25. Abamecha, A., Yilma, D., Adissu, W., Yewhalaw, D. & Abdissa, A. Efficacy and safety of
- 453 artemether-lumefantrine for treatment of uncomplicated *Plasmodium falciparum* malaria in
  454 Ethiopia: a systematic review and meta-analysis. *Malar. J.* 20, 213 (2021).
- 455 26. Bayih, A. G. *et al.* A unique *Plasmodium falciparum K13* gene mutation in northwest Ethiopia. *Am.*456 *J. Trop. Med. Hyg.* 94, 132–135 (2016).
- 457 27. Alemayehu, A. A. *et al.* Expansion of the *Plasmodium falciparum Kelch 13* R622I mutation in
  458 northwest Ethiopia. (2021) doi:10.21203/rs.3.rs-171038/v1.
- 459 28. Aydemir, O. et al. Drug-resistance and population structure of *Plasmodium falciparum* across the

- 460 Democratic Republic of Congo using high-throughput molecular inversion probes. J. Infect. Dis.
  461 218, 946–955 (2018).
- 462 29. Verity, R. *et al.* The impact of antimalarial resistance on the genetic structure of *Plasmodium*463 *falciparum* in the DRC. *Nat. Commun.* 11, 2107 (2020).
- 464 30. Malmberg, M. *et al. Plasmodium falciparum* drug resistance phenotype as assessed by patient
- 465 antimalarial drug levels and its association with *pfmdr1* polymorphisms. J. Infect. Dis. 207, 842–
  466 847 (2013).
- 467 31. Miotto, O. *et al.* Genetic architecture of artemisinin-resistant *Plasmodium falciparum. Nat. Genet.*468 47, 226–234 (2015).
- 469 32. Poti, K. E., Sullivan, D. J., Dondorp, A. M. & Woodrow, C. J. HRP2: Transforming malaria
  470 diagnosis, but with Caveats. *Trends Parasitol.* 36, 112–126 (2020).

471 33. World Health Organization. Data on antimalarial drug efficacy and drug resistance (2010–2019).
472 http://www.jstor.org/stable/resrep30095.10 (2020).


- 473 34. Anderson, T. J. *et al.* Microsatellite markers reveal a spectrum of population structures in the
  474 malaria parasite *Plasmodium falciparum*. *Mol. Biol. Evol.* 17, 1467–1482 (2000).
- 475 35. Cohen, J. M. *et al.* Malaria resurgence: a systematic review and assessment of its causes. *Malar. J.*476 11, 122 (2012).
- 477 36. Wasakul, V. *et al.* Malaria outbreak in Laos driven by a selective sweep for *Plasmodium falciparum*478 *kelch13* R539T mutants: a genetic epidemiology analysis. *Lancet Infect. Dis.* (2022)

doi:10.1016/S1473-3099(22)00697-1.

- 480 37. Ashley, E. A. *et al.* Spread of artemisinin resistance in *Plasmodium falciparum* malaria. *N. Engl. J.*481 *Med.* 371, 411–423 (2014).
- 38. Okell, L. C. *et al.* Emerging implications of policies on malaria treatment: genetic changes in the *Pfmdr-1* gene affecting susceptibility to artemether-lumefantrine and artesunate-amodiaquine in
  Africa. *BMJ Glob Health* 3, e000999 (2018).
- 485 39. Veiga, M. I. *et al.* Globally prevalent *PfMDR1* mutations modulate *Plasmodium falciparum*486 susceptibility to artemisinin-based combination therapies. *Nat. Commun.* 7, 115-53 (2016).
- 487 40. Nkhoma, S. C. *et al.* Close kinship within multiple-genotype malaria parasite infections. *Proc. Biol.*488 *Sci.* 279, 2589–2598 (2012).
- 489 41. Camponovo, F., Buckee, C. O. & Taylor, A. R. Measurably recombining malaria parasites. *Trends*490 *Parasitol.* 39, 17–25 (2023).


- 491 42. Rogier, E. et al. Plasmodium falciparum pfhrp2 and pfhrp3 gene deletions from persons with
- 492 symptomatic malaria infection in Ethiopia, Kenya, Madagascar, and Rwanda. *Emerg. Infect. Dis.*493 28, 608–616 (2022).
- 43. Halsey, E. S. *et al.* Capacity development through the US President's malaria initiative-supported
  antimalarial resistance monitoring in Africa network. *Emerg. Infect. Dis.* 23, (2017).
- 496 44. Verity, R. *et al.* The impact of antimalarial resistance on the genetic structure of *Plasmodium*497 *falciparum* in the DRC. *Nat. Commun.* 11, 2107 (2020).
- 498 45. Li, H. & Durbin, R. Fast and accurate long-read alignment with Burrows–Wheeler transform.
  499 *Bioinformatics* 26, 589–595 (2010).
- 500 46. Garrison, E. & Marth, G. Haplotype-based variant detection from short-read sequencing. *arXiv [q-bio.GN]* (2012).
- 502 47. Knaus, B. J. & Grünwald, N. J. vcfr: a package to manipulate and visualize variant call format data
  503 in R. *Mol. Ecol. Resour.* 17, 44–53 (2017).
- 48. Conway, J. R., Lex, A. & Gehlenborg, N. UpSetR: an R package for the visualization of
  intersecting sets and their properties. *Bioinformatics* 33, 2938–2940 (2017).
- 506 49. Chang, H.-H. *et al.* THE REAL McCOIL: A method for the concurrent estimation of the
  507 complexity of infection and SNP allele frequency for malaria parasites. *PLoS Comput. Biol.* 13,
  508 e1005348 (2017).
- 509 50. Lee, S. & Bahlo, M. moimix: an R package for assessing clonality in high-throughput sequencing
  510 data. *moimix: an R package for assessing clonality in high.*
- 51. Zheng, X. *et al.* A high-performance computing toolset for relatedness and principal component
  analysis of SNP data. *Bioinformatics* 28, 3326–3328 (2012).
- 513 52. Pfeifer, B., Wittelsbürger, U., Ramos-Onsins, S. E. & Lercher, M. J. PopGenome: an efficient Swiss
  514 army knife for population genomic analyses in R. *Mol. Biol. Evol.* 31, 1929–1936 (2014).
- 515 53. Csárdi, G. & Nepusz, T. The igraph software package for complex network research. (2006).
- 516
- 517
- 518
- 519
- 520

# 521 FIGURES



523 Figure 1. Prevalence of K13 and key drug-resistance mutations in Ethiopia. A) Spatial distribution of 524 K13 622I mutation at the district (pie charts) and regional (bar plot) levels. Colors indicate mutation status, 525 and pie chart size is proportional to sample size per district. The black triangle indicates the location where K13 622I mutation was reported previously. B) Prevalence of nonsynonymous mutations across the K13 526 gene, colored according to WHO ACT resistance marker category. K13 gene annotation shows 1-350 527 528 amino-acid residues in the poorly conserved Plasmodium-specific region, and 350-726 residues in the beta propeller domain where validated resistance mutations are located. C) Prevalence of mutations across four 529 key P. falciparum genes associated with commonly used antimalarial drugs (colors). 530

531






**Figure 2. Frequency of key drug resistance mutations.** The number of times each combination of mutations was observed is displayed, including *K13* 622I *pfmdr1* N86 (wild), 184F (mutant), and D1246 (wild)); and *pfcrt* genes. Results from monogenomic or the dominant haplotype in polygenomic infections are shown. Only samples with complete genotypes across all loci are shown.

537

538

539






542 Figure 3. *K13* 622I mutation among *pfhrp2/3*-deleted and *pfhrp2/3 non*-deleted parasite populations.

**A**) Comparison of mean *K13* 622I mutation prevalence between pfhrp2/3 double and pfhrp2/3 non-deleted


544 parasite populations by district across three regions in Ethiopia. **B**) Relationship between pfhrp2/3 double-


deleted parasite prevalence and K13 622I mutation prevalence by district. Prevalence estimates are weighted. Orange points represent districts where a parasite harboring both *pfhrp2-/3*- deletion and *K13* 

547 622I mutations are observed.



PC1(7.3%)





562 Figure 5. Pairwise IBD sharing and relatedness networks suggest clonal transmission and expansion of K13 622I parasites. A) Pairwise IBD sharing across all three regions of Ethiopia. The plot shows the 563 564 probability that any two isolates are identical by descent, where the x-axis indicates IBD values ranging from 0-1 and y-axis indicates the frequency (%) isolates sharing IBD. The inset highlights highly related 565 parasite pairs, with a heavy tail in the distribution and some highly related pairs of samples having IBD  $\geq$ 566 0.95. B) Pairwise IBD sharing within parasites carrying K13 622I vs. wild-type. Boxes indicate the 567 interquartile range, the line indicates the median, the whiskers show the 95% confidence intervals, and 568 569 black dots show outlier values. P value determined using Mann-Whitney test is shown. C) Relatedness network of highly related parasite pairs sharing IBD  $\geq 0.95$ . Colors correspond to K13 622I mutant and 570 571 wild parasites. **D)** Relatedness network of only K13 622I parasite pairs sharing IBD > 0.95 at the district level/local scale. Colors correspond to districts across three regions in Ethiopia. In both panels C and D, 572 each node identifies a unique isolate, and an edge is drawn between two isolates if they share their genome 573 574 above IBD  $\geq 0.95$ . Isolates that do not share IBD  $\geq 0.95$  their genome with any other isolates are not 575 shown.

576

561

577

medRxiv preprint doi: https://doi.org/10.1101/2023.03.02.23286711; this version posted March 5, 2023. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-NC-ND 4.0 International license.




Figure 6. Pairwise IBD sharing and relatedness networks suggest independent emergence and clonal spread of pfhrp2/3-deleted parasites. A) Pairwise IBD sharing by pfhrp2/3 deletion status. Boxes indicate the interquartile range, the line indicates the median, the whiskers show the 95% confidence intervals, and black dots show outlier values. P values were determined using the Kruskal-Wallis test. B) Relatedness network of highly related parasite pairs sharing IBD  $\geq 0.95$ . Each node identifies a unique isolate, and an edge is drawn between two isolates if they share their genome with IBD > 0.95. Isolates that do not share their genome IBD  $\ge 0.95$  with any other isolates are not shown. Color codes correspond to *pfhrp2/3* deletion status. C) Relatedness network of *pfhrp2/3* double-deleted parasite pairs with IBD  $\geq$ 0.95 at district level/local scale. Colors correspond to districts across three regions of Ethiopia.



- - -

# 603 SUPPLEMENTARY MATERIAL

# 604 Supplementary Tables

- 605 *Supplementary tables are compiled into a single file for ease of viewing.*
- **Table S1.** Prevalence of monogenomic infections per district weighted by RDT discordant prevalence.

607 Table S2. Weighted prevalence of key drug resistance mutations per district. Weighting calculated by608 RDT profile (see Methods).

- 609 Table S3. District level prevalence (unweighted) of all nonsynonymous mutations across different drug
- 610 resistance genes. The prevalence of antimalarial resistance mutations detected by the MIPs is shown for
- 611 each geographic location. Mutations above 1% prevalence in any of the districts shown. AA = mino Acid;
- n = number of samples genotyped; m = number of samples carry mutant allele.
- 613

# 614 Supplementary Data

- 615 *Supplementary tables are compiled into a single file for ease of viewing.*
- 616 **Data 1**. List of loci included in genome wide MIP panel.
- 617 Data 2. List of loci included in drug resistance MIP panel.

**Data 3.** Metadata for 609 successfully sequenced samples using the genome wide MIP panel. This data
was used for COI estimation and population genetic analysis.

620 Data 4. Metadata and genotype file for all successfully sequenced samples (varies per marker) using the

- 621 drug resistance MIP panel. Only successfully sequenced samples were used for drug resistance marker
- 622 prevalence estimates. 0 = Reference Call, 1 = Alternative heterozygous call, 2= Alternative homozygous
  623 call, -1 = Missing call.
- 624
- 625

# 626

# 627 Supplementary Figures







Figure S1. Description of sequenced samples. Spatial distribution of sequenced samples at district level (colordots in map) and regional level (color bar plot). Colors indicate regions.






632 Figure S2. PCR parasitemia distribution and association between sequencing coverage and parasitaemia.


A) Density plot showing parasitemia distribution with median parasitemia = 1411 parasite/ul. B) Association
 between sequencing coverage and parasitaemia. The MIP sequencing success is parasitaemia dependent as shown


635 in the heatmap color.



636

Figure S3. Sample (A) and SNP (B) missingness. A) Samples with >50% low-coverage loci were dropped as
shown broken read line. B) Variant sites were then assessed by the same means in terms of the proportion of lowcoverage samples, and sites with >50% low-coverage samples were dropped. Broken read line shows 50%
threshold criteria we used to remove samples and loci from downstream analyses.





- 643 A) Association between sequencing coverage and parasitaemia. The MIP sequencing success is parasitaemia
- 644 dependent as shown in the heatmap color. **B**) Distribution of retained SNPs across *Plasmodium falciparum*
- 645 chromosomes. The plot shows distribution of 1395 retained high quality biallelic SNPs across the 14 *P*.
- 646 *falciparum* chromosomes within 0.025 Mb window size. Color coded from light gray for masked regions with no
- 647 SNPs to red for regions containing high number SNPs per chromosome.




Figure S5. Complexity of infections. A) Distribution Number of clones per sample across genotyped samples
 showing most of isolates carrying one clone (COI=1). B) Cumulative within-infection FWS fixation showing
 majority of isolates classified as monogenomic (FWS > 0.95). Number of clones per sample. C) Spatial
 heterogeneity of mean complexity of infections per district across three regions in Ethiopia. Vertical lines show 95%
 confidence intervals.






Figure S6. Prevalence of *Pfdhfr* and *Pfdhps* mutations across Ethiopia. A) UpSet plots showing the number of
times each combination of mutations was seen for *Pfdhfr* and *Pfdhps*. B) Spatial distribution of *Pfdhps A581G*mutation at district level. Colors indicate mutation status and size of pie chart is proportional to sample size per
district.




658







667



669

670 Figure S8. Population structure of *P. falciparum in* Ethiopia. A) Principal component analysis *P. falciparum*671 populations per region. Colors indicate sample origin and shape indicates *K13* 622I mutation status (circle indicates
672 wild and diamond indicates mutant). Percentage of variance explained by each principal component presented (%).
673 B) Percent of overall variance explained by the first 10 principal components during PCA.

674




Figure S9. PCA loading values. PC1 (A) and PC2 (B) are shown by SNP. Cutoffs show SNPs that highlycontribute to positive or negative distribution of samples in the PC plots.